• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺局限性癌的诊断和治疗窗口期。

The diagnostic and therapeutic window for localized carcinoma of the prostate.

作者信息

Schmid H P

机构信息

Division of Urology, University of Basel, Suisse.

出版信息

Ann Urol (Paris). 1994;28(4):178-83.

PMID:7526772
Abstract

The natural history of prostate cancer has been regarded as unpredictable for a long period of time. The discrepancy between histologically identifiable (40%) and clinically diagnosed carcinomas (8%) led to the term of "latent" prostate cancer and to a considerable diagnostic and therapeutic dilemma. Based on previous studies showing that biological aggressiveness of prostate cancer is a direct function of tumor volume and that tumor volume and serum-PSA are proportional, two basically different groups of patients were evaluated. The first group consisted of 43 patients with untreated carcinomas of the prostate followed with serial PSA determinations. The exponential (log-linear) rise in PSA led to the conclusion of an exponential tumor growth rate. The median doubling time of clinically organ-confined tumors was 4 years and became shorter with higher clinical stages and poorly differentiated histological grades. The second group consisted of 139 patients who underwent cystoprostatectomy for bladder cancer and had no evidence for simultaneously identifiable prostate cancer. In 55 patients (40%) unsuspected prostate cancer was found in the specimen; the volume distribution of these carcinomas was exponential. Eleven of the 139 men (7.9%) had a prostate cancer greater than 0.5 cc, corresponding to the 8% risk for a man being diagnosed within his life-time with a clinically significant carcinoma of the prostate. In conclusion, the other 44 carcinomas below 0.5 cc may never reach clinical significance due to their small size and their long doubling time; in this sense they can be considered "latent".(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

长期以来,前列腺癌的自然病史一直被认为是不可预测的。组织学可识别的癌(40%)与临床诊断的癌(8%)之间的差异导致了“潜伏性”前列腺癌这一术语的出现,并引发了相当大的诊断和治疗困境。基于此前的研究表明前列腺癌的生物学侵袭性是肿瘤体积的直接函数,且肿瘤体积与血清前列腺特异抗原(PSA)成正比,对两组基本不同的患者进行了评估。第一组由43例未经治疗的前列腺癌患者组成,对其进行连续的PSA测定随访。PSA呈指数(对数线性)上升,由此得出肿瘤生长速度呈指数增长的结论。临床局限于器官内的肿瘤的中位倍增时间为4年,随着临床分期升高和组织学分级差,该时间会缩短。第二组由139例因膀胱癌接受膀胱前列腺切除术且无同时可识别前列腺癌证据的患者组成。在55例患者(40%)的标本中发现了意外的前列腺癌;这些癌的体积分布呈指数分布。139名男性中有11名(7.9%)患有大于0.5立方厘米的前列腺癌,这与男性一生中被诊断出患有具有临床意义的前列腺癌的8%风险相对应。总之,其他44例体积小于0.5立方厘米的癌可能因其体积小和倍增时间长而永远不会达到临床意义;从这个意义上说,它们可被视为“潜伏性”的。(摘要截选至250词)

相似文献

1
The diagnostic and therapeutic window for localized carcinoma of the prostate.前列腺局限性癌的诊断和治疗窗口期。
Ann Urol (Paris). 1994;28(4):178-83.
2
[Natural follow-up of prostate cancer and consequences for early detection].[前列腺癌的自然随访及其对早期检测的影响]
Schweiz Rundsch Med Prax. 1993 Nov 2;82(44):1239-43.
3
[Effect of the natural history on management of adenocarcinoma of the prostate].[自然病程对前列腺腺癌治疗的影响]
Urologe A. 1994 Mar;33(2):144-8.
4
Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer.膀胱癌患者与非膀胱癌患者临床可检测前列腺癌患病率的比较研究。
Urology. 2004 Feb;63(2):268-72. doi: 10.1016/j.urology.2003.09.027.
5
Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.接受延期治疗患者的肿瘤标志物:前列腺特异性抗原倍增时间
Cancer Surv. 1995;23:157-67.
6
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.术前血清前列腺特异性抗原水平在2至22纳克/毫升之间与根治性前列腺切除术后的癌症形态相关性较差:前列腺特异性抗原治愈率在2至9纳克/毫升之间似乎保持不变。
J Urol. 2002 Jan;167(1):103-11.
7
Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.前列腺癌核分级与根治性前列腺切除术后前列腺特异性抗原复发之间无相关性。
J Urol. 2001 Dec;166(6):2193-7.
8
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?膀胱前列腺切除术时偶然发现的血清前列腺特异性抗原水平极低(0 - 2 ng/mL)的前列腺癌的病理特征:前列腺特异性抗原是临床意义的有用指标吗?
Urol Oncol. 2004 Jan-Feb;22(1):40-7. doi: 10.1016/S1078-1439(03)00093-0.
9
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.前列腺特异性抗原密度与前列腺癌侵袭性特征相关。
J Urol. 2007 Feb;177(2):505-9. doi: 10.1016/j.juro.2006.09.039.
10
Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.基于体积的血清检测新前列腺特异性抗原异构体在前列腺癌检测中的评估。
Urology. 2004 Mar;63(3):492-8. doi: 10.1016/j.urology.2003.10.044.